We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors
News

Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors

Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors
News

Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Idera Pharmaceuticals, Inc. has announced the issuance of US patent 7,276,489 (the ‘489 patent) for novel oligonucleotide compositions. The claims of this patent, entitled “Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds By Optimal Presentation of 5’ Ends,” cover oligonucleotide compositions in which two oligonucleotides are attached together through their 3’ ends and contain various synthetic immune stimulatory motifs.

These claims provide additional protection for the Company’s TLR9-targeted compounds, including its two lead product candidates, IMO-2055 and IMO-2125.

“We are pleased to have received the claims of the ‘489 patent for novel structures of oligonucleotide compositions,’” said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer.

“The claims of the ‘489 patent and our previously issued patents (e.g. US7,262,286; US7,176,296; US7,115,579; US7,105,495) are the result of our chemistry-based approach in identifying TLR9-targeted compounds. We are using the technologies claimed in our patents and patent applications to design novel compounds for our internal programs and for partnered programs.”

Advertisement